- $314.08m
- $175.27m
- 54
- 23
- 53
- 39
Annual cashflow statement for Korro Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -18.7 | -26.5 | -84.7 | -81.6 | -81.2 |
| Depreciation | |||||
| Non-Cash Items | 3.5 | 10.4 | 23.2 | 22.6 | 5.98 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 48.6 | -30.2 | -17.3 | -2.02 | 4.28 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 34.2 | -45.2 | -76.1 | -58.2 | -67.3 |
| Capital Expenditures | -1.06 | -6.67 | -2.91 | 0 | -7.84 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -17.2 | 17.1 | -63.2 | 31.1 | 19 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -18.3 | 10.4 | -66.1 | 31.1 | 11.2 |
| Financing Cash Flow Items | 0 | — | 0.06 | 0.196 | 24.4 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 142 | 56.7 | 1.36 | -0.577 | 188 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 158 | 21.9 | -141 | -27.7 | 132 |